miR-483-3p Promotes IL-33 Production from Fibroblast-Like Synoviocytes by Regulating ERK Signaling in Rheumatoid Arthritis

Kailin Zhang,1 WenYi Fu,2 Shuai Zhao,2 Ting Jiao,2 Dan Wu,2 and YueJiao Wang2,3

Received 30 December 2020; accepted 10 June 2021

Abstract—Our previous studies have identified miR-483-3p to be highly expressed in synoviocytes from patients with rheumatoid arthritis (RA); however, its effects on inflammation of RA fibroblast-like synoviocytes (FLSs) have remained unclear. The expression of miR-483-3p and cytokines in RA FLSs was detected using quantitative real-time polymerase chain reaction. Enzyme-linked immunosorbent was conducted to determine interleukin (IL)-33 production from RA FLSs. Western blotting was employed to quantify the levels of p-ERK and total ERK. Overexpressed miR-483-3p significantly increased the mRNA and protein expression of IL-33, but not of IL-27 or IL-34, in RA FLSs, whereas miR-483-3p suppression showed the opposite effects. Furthermore, miR-483-3p upregulation activated the ERK signaling pathway. The ERK signaling inhibitor PD98059 partly reversed the elevation of IL-33 levels mediated by miR-483-3p overexpression. Our results reveal that miR-483-3p promotes IL-33 expression by regulating the ERK signaling pathway in RA FLSs. Thus, miR-483-3p may be a potential effective target for RA treatment.

KEY WORDS: miR-483-3p; synoviocytes; rheumatoid arthritis; ERK signaling.

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic disease that affects several organs and tissues, predominantly the joints, in 0.5–1% of the population worldwide [1]. As one of the most common autoimmune diseases, RA is characterized by persistent synovitis, systemic inflammation, and autoantibody production [2]. The global burden of RA, measured by incidence, complications, and expenses, is substantial and constantly on the rise [3]. Due to the development of comprehensive treatment methodologies in the past decades, clinical outcomes of patients with RA have significantly improved [4]. However, some patients still fail to achieve total remission with persistent synovial inflammation.

Dysfunction of synovial tissues is the basis for the persistent inflammation and pannus formation in RA [5]. The normal synovium, a thin membrane lining the joint capsule, consists of two cell populations, namely fibroblast-like synoviocytes (FLSs) and macrophage-like synoviocytes. FLSs are critical in the pathogenesis of RA.
Distinct from other inflammatory arthritis, FLSs from patients with RA show aggressive tumor cell-like features, such as excessive proliferation, resistance to cell death, and inflammatory cytokine secretion [7]. Therefore, identifying novel potential target molecules in RA FLSs would be of great importance in this field.

MicroRNAs (miRNAs), defined as small non-coding RNAs 18-25 nt in length, modulate gene expression through degradation or translational repression of mRNA [8]. Accumulating evidence has indicated miRNAs to be associated with the occurrence and development of RA by regulating several physiological and pathological processes in RA FLSs, such as cell proliferation, migration, invasion, and inflammation [9, 10]. Our previous studies had identified miR-483-3p as a dysregulated miRNA in synovial tissues and FLSs from patients with RA [11]. Through gain- and loss-of-function assays, we could demonstrate the promotion of cell proliferation and suppression apoptosis by miR-483-3p in RA FLSs. However, the precise roles of miR-483-3p in the inflammation of RA FLSs are still unknown.

In this study, we demonstrated that miR-483-3p promoted the inflammatory cytokine secretion from FLSs by regulating the ERK signaling pathway in RA. Overall, we suggest miR-483-3p to potentially serve as a promising therapeutic target for patients with RA.

MATERIALS AND METHODS

Cell Culture

Healthy FLSs (HFLS) and immortalized RA FLSs (HFLS-RA) were purchased from the Jennio Biotech Co., Ltd. (Guangzhou, China). They were cultured in MEM (Corning, USA) and DMEM (Corning), respectively, at 37 °C in a 5% CO2 incubator. LPS (1 μg/mL) and TNF-α (10 ng/mL) (Sigma-Aldrich, St. Louis, USA) were used to stimulate HFLS-RA cells, respectively.

Cell Transfection

miR-483-3p mimics, mimics negative control (NC), inhibitor and inhibitor NC were commercially obtained from GenePharma (Suzhou, China) and transfected into HFLS-RA using jetPRIME reagent (Polyplus, Illkirch, France) according to the manufacturer’s instructions.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Total RNA isolation from HFLS and HFLS-RA, reverse transcription, and quantitation of target genes were conducted as described previously [11]. GAPDH and U6 were used as controls for IL-33 and miR-483-3p expression, respectively. The primers commercially obtained from Sangon Biotech (Shanghai, China) were as follows: 5′-AGACGCCAGGCAGCATTT-3′ (forward) and 5′-GGCTGACTGTAACCTCCCTC-3′ (reverse) for IL-27; 5′-GTGACGGTGGATGGTAAGAT-3′ (forward) and 5′-AGCTCCACAGAGTGTCTTGG-3′ (reverse) for IL-33; 5′-AAAACAAAGCTCCGTCCTAAACTG-3′ (forward) and 5′-GCCGCATAACTGCAATGGAGG-3′ (reverse) for IL-34; 5′-ACAACCTTGGATCCGTGGAA GG-3′ (forward) and 5′-GCCATCACGCCACAGTTC-3′ (reverse) for GAPDH; 5′-TCACTTCTCCCTTC CCTGCTT-3′ (forward) for miR-483-3p. Relative expression of genes was calculated using the 2-ΔΔCt method.

Enzyme-Linked Immunosorbent Assay (ELISA)

The cell culture supernatant from HFLS-RA was collected as described previously [12]. Concentration of IL-33 in the supernatants was detected using an ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions.

Western Blotting

HFLS-RA, under different treatments, were lysed with RIPA buffer (Solarbio, China) to obtain the total protein; a BCA kit (Solarbio) was used to quantify the levels of total protein. Approximately 30 μg of protein was separated through SDS-PAGE (Solarbio) and transferred to PVDF membranes. The membranes were then incubated with primary antibodies against ERK1/2 (1:1000) (Proteintech, China), p-ERK1/2 (1:1000) (Proteintech) and GAPDH (1:5000) (Proteintech), and subsequently with secondary antibodies (Proteintech).

Statistical Analysis

All experiments were conducted independently at least thrice. The Student’s t test and one-way analysis of variance followed by Dunn’s multiple comparison post-hoc test were used to compare the significance of differences across two and multiple groups, respectively. GraphPad Prism (v.8.0, CA) was used to analyze the data. p < 0.05 was considered statistically significant.
RESULTS

miR-483-3p Was Highly Expressed in RA FLSs

As shown in Fig. 1a, HFLS-RA had a higher miR-483-3p expression than HFLS (p < 0.05). Furthermore, the expression of miR-483-3p was further increased in HFLS-RA after treatment with LPS (p < 0.01, Fig. 1b) and with TNF-α (p < 0.01, Fig. 1c), suggesting that dysregulated miR-483-3p might be involved in the pathogenesis of RA.

miR-483-3p Promoted Inflammation of RA FLSs by Regulating IL-33

In order to explore the role of miR-483-3p in inflammation, we first manipulated the expression of miR-483-3p in HFLS-RA. As shown in Fig. 2a, mimics treatment significantly increases miR-483-3p levels in HFLS-RA (p < 0.0001), while inhibitor treatment decreases the miR-483-3p levels (p < 0.0001). Next, we explored the role of miR-483-3p in inflammation by measuring the levels of cytokines, including IL-27, IL-33, and IL-34. qRT-PCR assays showed that IL-33 expression, but not IL-27 (p > 0.05, Fig. 2b) or IL-34 (p > 0.05, Fig. 2c) expression, was upregulated in the mimics group (p < 0.001, Fig. 2d) and downregulated in the inhibitor group (p < 0.05). Consistently, the secretion of IL-33 from HFLS-RA was increased in the mimics group (p < 0.0001, Fig. 2e) and decreased in the inhibitor group (p < 0.01) compared to that in the NC groups. These results indicated the promotion of RA FLSs inflammation to occur via IL-33 induction.

miR-483-3p Activated the ERK Signaling Pathway in RA FLSs

Since ERK signaling activation is commonly involved in RA-related inflammation [13], we evaluated the role of miR-483-3p in ERK signaling. As shown in Fig. 3, the levels of p-ERK1/2 were significantly unregulated in the mimics group (p < 0.0001, Fig. 3a and c) and downregulated in the inhibitor group compared to that in the NC groups. However, the levels of total ERK showed no significant difference (p > 0.05, Fig. 3a and b). These results demonstrated the activation of ERK signaling was mediated by miR-483-3p in RA FLSs.

miR-483-3p Promoted IL-33 Levels in RA FLSs by Activating the ERK Signaling Pathway

To confirm whether miR-483-3p regulated the inflammation of RA FLSs through ERK signaling, rescue assays were performed with PD98059, an ERK signaling pathway inhibitor. As shown in Fig. 4a–c, PD98059 treatment significantly suppressed the levels of p-ERK1/2 (p < 0.001), although not of total ERK1/2 (p > 0.05), in HFLS-RA. Notably, PD98059 treatment significantly rescued the upregulation of IL-33, at both mRNA and protein levels, after being induced by miR-483-3p mimics (both p < 0.05, Fig. 4d and e), thereby suggesting that promotion of IL-33 levels in RA FLSs by miR-483-3p occurred via activation of the ERK signaling pathway.

DISCUSSION

Persistent synovial inflammation is a unique hallmark of RA pathology, resulting in progression of the disease
and, eventually, deformity of joints [14]. FLSs are important non-immune cells mainly located in the synovium, whose interaction with immune and non-immune cells leads to synovial hyperplasia, pannus formation, and of proinflammatory cytokine secretion in patients with RA [15].

Recent studies have suggested that miRNAs are involved in the inflammatory responses of RA FLSs. Najm A et al. had identified miR-17 as a low expression miRNA that exerted anti-inflammatory effect by suppressing the IL-6 and IL-1β expression in RA FLSs [10]. Tsai MH et al. had demonstrated that miR-137 downregulated IL-6 and cyclooxygenase-II (COX-II) levels in RA FLSs [16]. Additionally, our previous study had reported the suppression of tumor necrosis factor (TNF)-α, IL-1β, IL-6, and metalloprotease (MMP)-9 levels in RA FLSs by miR-410-3p via NF-κB signaling [12]. Particularly, some novel ILs have been associated with miRNAs in RA. Yang et al.
had demonstrated a positive correlation between miR-21 and IL-34 in patients with RA [17]; Figueiredo et al. had reported that miR-29b, miR-21, and miR-20b were involved to regulate the function of IL-27 in inflammation of RA [18]. Therefore, we planned to explore the association of miR-483-3p with these relatively novel ILs. In this study, we confirm that miR-483-3p promotes inflammation in RA FLSs by regulating the expression of IL-33, but not of IL-27 or IL-34.

IL-33 has been confirmed to be highly expressed in blood serum, synovial fluid, and FLSs of patients with RA [19–22]; additionally, it is associated with disease activity, autoantibody production, and response to drugs [23]. Wu S et al. had reported that IL-33 promotes proliferation and inhibits apoptosis of RA FLSs by regulating NF-κB signaling [24], suggesting that IL-33 plays its role as a proinflammatory cytokine in RA FLSs. Recent studies have found that IL-33 production might be promoted via ERK signaling pathway activation [25]. Furthermore, abnormal activation of the ERK signaling pathway has been reported to regulate cell proliferation, apoptosis, migration, invasion, and inflammation in RA [26, 27]. Therefore, we speculated that promotion of IL-33 levels by miR-483-3p could be mediated by ERK signaling pathway. In our study, we observed that overexpression of miR-483-3p activated the ERK signaling pathway in RA FLSs, and the ERK signaling inhibitor reversed the promotion of IL-33 production by miR-483-3p, hence confirming the promotion of IL-33 expression by miR-483-3p in RA FLSs to occur via ERK signaling pathway.

In conclusion, we found miR-483-3p to be highly expressed in RA FLSs, promoting IL-33 production in RA FLSs via the ERK signaling pathway. These findings together revealed miR-483-3p to play an important role in inflammation of RA FLSs, possibly representing an effective target for RA treatment.

AVAILABILITY OF DATA AND MATERIAL

Not applicable.

AUTHOR CONTRIBUTION

YW: conception and design of the research; KZ: acquisition of data and drafting the manuscript; KZ, TJ, and SZ: analysis and interpretation of data; DW: statistical
analysis; WF and YW: revision of manuscript for important intellectual content. All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**FUNDING.** This study was supported by grants from the Faculty Post-doctoral Research Startup Fund of China Medical University (No.M0470 to Yuejiao Wang) and the 345 Talent Project of Shengjing Hospital of China Medical University (No.M0686 to Yuejiao Wang).

**DECLARATIONS**

**Ethics Approval and Consent to Participate.** This study was performed according to the recommendations of the Declaration of Helsinki and approved by the Ethics Committee of Shengjing Hospital of China Medical University (2019PS637K).

**Consent for Publication.** Not Applicable.

**Conflict of Interest.** The authors declare no competing interests.

**REFERENCES**

1. Sparks, J.A. 2019. Rheumatoid arthritis. *Annals of Internal Medicine* 170 (1): ITC1–ITC16. https://doi.org/10.7326/AITC201901010.
2. Smolen, J.S., D. Aletaha, and I.B. McInnes. 2016. Rheumatoid arthritis. *Lancet* 388 (10055): 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8.
3. Saffiri, S., A.A. Kolahi, D. Hoy, E. Smith, D. Bettampadi, M.A. Mansournia, A. Almasi-Hashemi, A. Ashrafi-Asgarabad, M. Moradi-Lakeh, M. Qorbani, G. Collins, A.D. Woolf, L. March, and M. Cross. 2019. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the global burden of disease study 2017. *Annals of the Rheumatic Diseases* 78 (11): 1463–1471. https://doi.org/10.1136/annrheumdis-2019-215920.
4. Goll, G.L., and T.K. Kvien. 2020. What next after biologic therapy fails in rheumatoid arthritis? *The New England Journal of Medicine* 383 (16): 1588–1589. https://doi.org/10.1056/NEJMc2026142.
5. García-Carbonell, R., A.S. Divakaruni, A. Lodi, I. Vicente-Suárez, A. Saha, H. Cheroutre, G.R. Boss, S. Tiziani, A.N. Murphy, and M. Guma. 2016. Critical role of glucose metabolism in rheumatoid arthritis fibroblast-like synoviocytes. *Arthritis & Rheumatology* 68 (7): 1614–1626. https://doi.org/10.1002/art.39608.
6. Bottini, N., and G.S. Firestein. 2013. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. *Nature Reviews Rheumatology* 9 (1): 24–33. https://doi.org/10.1038/nrrheum.2012.190.
7. Chu, C.Q. 2020. Fibroblasts in rheumatoid arthritis. *The New England Journal of Medicine* 383 (17): 1679–1681. https://doi.org/10.1056/NEJMcbr2024718.
8. Xiao, C., and K. Rajewsky. 2009. MicroRNA control in the immune system: basic principles. *Cell* 136 (1): 26–36. https://doi.org/10.1016/j.cell.2008.12.027.
9. Chen, J., M. Liu, X. Luo, L. Peng, Z. Zhao, C. He, and Y. He. 2020. Exosomal miRNA-486-5p derived from rheumatoid arthritis fibroblast-like synoviocytes induces osteoblast differentiation through the Tnb1/BMP/Smad pathway. *Biomaterials Science* 8 (12): 3430–3442. https://doi.org/10.1039/c9bm01761e.
10. Najm, A., F.M. Masson, P. Preuss, S. Georges, B. Ory, T. Quillard, S. Sood, C.S. Goodyear, D.J. Veale, U. Fearon, B. le Goff, and F. Blanchard. 2020. MicroRNA-17-5p reduces inflammation and bone erosions in mice with collagen-induced arthritis and directly targets the JAK/STAT pathway in rheumatoid arthritis fibroblast-like synoviocytes. *Arthritis & Rheumatology* 72 (12): 2030–2039. https://doi.org/10.1002/art.41441.
11. Wang, Y., L. Hou, X. Yuan, N. Xu, S. Zhao, L. Yang, and N. Zhang. 2020. miR-483-3p promotes cell proliferation and suppresses apoptosis in rheumatoid arthritis fibroblast-like synoviocytes by targeting IGF-1. *Biomedicine & Pharmacotherapy* 130: 110519. https://doi.org/10.1016/j.biopha.2020.110519.
12. Wang, Y., N. Xu, S. Zhao, T. Jiao, W. Fu, L. Yang, and N. Zhang. 2019. miR-410-3p Suppresses cytokine release from fibroblast-like synoviocytes by regulating nf-kappaB signaling in rheumatoid arthritis. *Inflammation* 42 (1): 331–341. https://doi.org/10.1007/s10753-018-0896-2.
13. Lim, H.J., S.G. Bak, H.J. Lim, S.W. Lee, S. Lee, S.K. Ku, S.I. Park, S.J. Lee, and M.C. Rho. 2020. Acyclic triterpenoid isolated from Alpinia katsumadai alleviates formalin-induced chronic mouse paw inflammation by inhibiting the phosphorylation of ERK and NF-kappaB. *Molecules* 25 (15). https://doi.org/10.3390/molecules25153345.
14. Buch, M.H., S. Eyre, and D. McGonagle. 2021. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. *Nature Reviews Rheumatology* 17 (1): 17–33. https://doi.org/10.1038/s41583-020-00541-7.
15. Takeuchi, Y., K. Hirota, and S. Sakaguchi. 2019. Synovial tissue inflammation mediated by autoinimmune T cells. *Frontiers in Immunology* 10: 1989. https://doi.org/10.3389/fimmu.2019.01989.
16. Tsai, M.H., M.C. Chi, J.F. Hsu, I.T. Lee, K.M. Lin, M.L. Fang, M.H. Lee, C.W. Lee, and J.F. Liu. 2020. Urban particulate matter enhances ROS/IL-6/COX-II production by inhibiting microRNA-137 molecules. *Science China Chemistry* 63 (9): 1366–1376. https://doi.org/10.1007/s11426-019-1747-4.
17. Yang, S., S. Jiang, Y. Wang, S. Tu, Z. Wang, and Z. Chen. 2016. Interleukin 34 upregulation contributes to the increase of microRNA 21 expression through stat3 activation associated with disease activity in rheumatoid arthritis. *The Journal of Rheumatology* 43 (7): 1312–1319. https://doi.org/10.3899/jrheum.151253.
18. Figueiredo Neto, M., and M.L. Figueiredo. 2017. Combination of interleukin-27 and microRNA for enhancing expression of anti-inflammatory and proosteogenic genes. *Arthritis 2017*: 6365857–6365813. https://doi.org/10.1155/2017/6365857.
19. Riviere, E., J. Sellam, J. Pascuald, P. Ravaud, J.E. Gottenberg, and X. Mariette. 2018. Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis. *Arthritis Research & Therapy* 20 (1): 122. https://doi.org/10.1186/s13075-018-1628-6.
20. Talatab-Ayer, D., T. McKee, P. Gindre, S. Bas, D.L. Baeten, C. Gabay, and G. Palmer. 2012. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis
21. Kunisch, E., S. Chakilam, M. Gandesiri, and R.W. Kinne. 2012. IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts. *International Journal of Molecular Medicine* 29 (4): 530–540. https://doi.org/10.3892/ijmm.2012.883.

22. Murdaca, G., M. Greco, A. Tonacci, S. Negrini, M. Borro, F. Puppo, and S. Gangemi. 2019. IL-33/IL-31 Axis in immune-mediated and allergic diseases. *International Journal of Molecular Sciences* 20 (23). https://doi.org/10.3390/ijms20235856.

23. Sellam, J., E. Riviere, A. Courties, P.O. Rouzaire, B. Tolusso, E.M. Vital, P. Emery, et al. 2016. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. *Arthritis Research & Therapy* 18 (1): 294. https://doi.org/10.1186/s13075-016-1190-z.

24. Wu, S., Y. Jiang, Y. Teng, X. Liu, L. Zhou, and W. Li. 2020. Interleukin-33 promotes proliferation and inhibits apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis. *Clinical and Experimental Rheumatology*

25. Lv, Y.P., Y.S. Teng, F.Y. Mao, L.S. Peng, J.Y. Zhang, P. Cheng, Y.G. Liu, H. Kong, T.T. Wang, X.L. Wu, C.J. Hao, W. Chen, S.M. Yang, Y.L. Zhao, B. Han, Q. Ma, Q.M. Zou, and Y. Zhuang. 2018. Helicobacter pylori-induced IL-33 modulates mast cell responses, benefits bacterial growth, and contributes to gastritis. *Cell Death & Disease* 9 (5): 457. https://doi.org/10.1038/s41419-018-0493-1.

26. Liu, F., X.X. Feng, S.L. Zhu, H.Y. Huang, Y.D. Chen, Y.F. Pan, R.R. June, S.G. Zheng, and J.L. Huang. 2018. Sonic hedgehog signaling pathway mediates proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis via MAPK/ERK signaling pathway. *Frontiers in Immunology* 9: 2847. https://doi.org/10.3389/fimmu.2018.02847.

27. Huang, C.C., C.H. Chiou, S.C. Liu, S.L. Hu, C.M. Su, C.H. Tsai, and C.H. Tang. 2019. Melatonin attenuates TNF-alpha and IL-1beta expression in synovial fibroblasts and diminishes cartilage degradation: implications for the treatment of rheumatoid arthritis. *Journal of Pineal Research* 66 (3): e12560. https://doi.org/10.1111/jpr.12560.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.